Document:

<PAGE>

                                                                    Exhibit 10.3
                                                                    ------------
                                ePRESENCE, INC.
                           2001 STOCK INCENTIVE PLAN

                     NON-STATUTORY STOCK OPTION AGREEMENT
                     ------------------------------------

     1.  GRANT OF OPTION.  ePresence, Inc., a Massachusetts corporation (the
         ---------------
"Company"), hereby grants to [NAME]  (the "Optionee") an option, pursuant to the
Company's 2001 Stock Incentive Plan (the "Plan"), to purchase an aggregate of
[NO] shares of Common Stock ("Common Stock") of the Company at a price of $[$]
per share, purchasable as set forth in and subject to the terms and conditions
of this option and the Plan.  The date of grant of this option is [DATE]. Except
where the context otherwise requires, the term "Company" shall include the
parent and all present and future subsidiaries of the Company as defined in
Sections 424 (e) and 424 (f) of the Internal Revenue Code of 1986, as amended or
replaced from time to time (the "Code").

     2.  NON-STATUTORY STOCK OPTION.  This option is not intended to qualify as
         --------------------------
an incentive stock option within the meaning of Section 422 of the Code.

     3.  EXERCISE OF OPTION AND PROVISIONS FOR TERMINATION.
         --------------------------------------------------

         a. Vesting Schedule.  Except as otherwise provided in this
            ----------------
Agreement, this option may be exercised prior to the tenth anniversary of the
date of grant (hereinafter the "Expiration Date") in installments as to not more
than the number of shares set forth in the table below during the respective
installment periods set forth in the table below.

                                      NUMBER OF SHARES AS TO
         EXERCISE PERIOD              WHICH OPTION IS EXERCISABLE
         ---------------              ---------------------------

         Vesting is variable depending upon the terms of the option.

The right of exercise shall be cumulative so that if the option is not exercised
to the maximum extent permissible during any exercise period, it shall be
exercisable, in whole or in part, with respect to all shares not so purchased at
any time prior to the Expiration Date or the earlier termination of this option.
This option may not be exercised at any time on or after the Expiration Date,
except as otherwise provided in Section 3 (e) below.

         b. Exercise Procedure.  Subject to the conditions set forth in this
            ------------------
Agreement, this option shall be exercised by the Optionee's delivery of written
notice of exercise to the Treasurer of the Company, specifying the number of
shares to be purchased and the purchase price to be paid therefor and
accompanies by payment in full in accordance with Section 4.  Such exercise
shall be effective upon receipt by the Treasurer of the Company of such written
notice together with the required payment.  The Optionee may purchase less than
the number of shares covered hereby, provided that no partial exercise of this
option may be for any fractional share or for fewer than ten whole shares.
<PAGE>

         c. Continuous Relationship with the Company Required.  Except as
            -------------------------------------------------
otherwise provided in this Section 3, this option may not be exercised unless
the Optionee, at the time he or she exercises this option, is, and has been at
all times since the date of grant of this option, an employee of, officer or
director of, or consultant or advisor to, the Company (an "Eligible Optionee").

         d. Termination of Relationship with the Company.  If the Optionee
            --------------------------------------------
ceases to be an Eligible Optionee for any reason, then, except as provided in
paragraphs (e) and (f) below, the right to exercise this option shall terminate
90 days after such cessation (but in no event after the Expiration Date),
provided that this option shall be exercisable only to the extent that the
Optionee was entitled to exercise this option on the date of such cessation.
Notwithstanding the foregoing, if the Optionee, prior to the Expiration Date,
materially violates the non-competition or confidentiality provisions of any
employment contract, confidentiality and nondisclosure agreement or other
agreement between the Optionee and the Company, the right to exercise this
option shall terminate immediately upon written notice to the Optionee from the
Company describing such violation.

         e. Exercise Period Upon Death or Disability.  If the Optionee dies or
            ----------------------------------------
becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to
the Expiration Date while he or she is an Eligible Employee, or if the Optionee
dies within 90 days after the Optionee ceases to be an Eligible Optionee (other
than as the result of a termination of such relationship by the Company for
"cause" as specified in paragraph (f) below), this option shall be exercisable,
within the period of one year following the date of death or disability of the
Optionee (whether or not such exercise occurs before the Expiration Date), by
the Optionee or by the person to whom this option is transferred by will or the
laws of descent and distribution, provided that this option shall be exercisable
only to the extent that this option was exercisable by the Optionee on the date
of his or her cessation of employment with the Company.  Except as otherwise
indicated by the context, the term "Optionee", as used in this option, shall be
deemed to include the estate of the Optionee or any person who acquires the
right to exercise this option by bequest or inheritance or otherwise by reason
of the death of the Optionee.

         f. Discharge for Cause.  If the Optionee, prior to the Expiration Date,
            -------------------
ceases his or her relationship with the Company because such relationship is
terminated by the Company for "cause" (as defined below), the right to exercise
this option shall terminate immediately upon such cessation.  "Cause" shall mean
willful misconduct by the Optionee or willful failure to perform his or her
responsibilities in the best interests of the Company (including, without
limitation, breach by the Optionee of any provision of any employment,
consulting, advisory, nondisclosure, non-competition or other similar agreement
between the Optionee and the Company), as determined by the Company, which
determination shall be conclusive.

     4.  PAYMENT OF PURCHASE PRICE.
         --------------------------

         a. Method of Payment.  Payment of the purchase price for shares
            -----------------
purchased upon exercise of this option shall be made by delivery of cash or
check (as determined by the Company in its sole discretion) in an amount equal
to the exercise price of such options or, with the prior consent of the Company
(which may be withheld in its sole discretion), by (A) delivery of vested shares
of Common Stock owned by the Optionee for at least six months, valued at their
fair market value, as determined pursuant to (b) below, (B) delivery of a
promissory note of the Optionee to the Company on terms determined by the
Compensation Committee of the

                                     Page 2
<PAGE>

Company's Board of Directors (the "Compensation Committee), (C) delivery of an
irrevocable undertaking by a broker to deliver promptly to the Company
sufficient funds to pay the exercise price or delivery of irrevocable
instructions to a broker to deliver promptly to the Company cash or a check
sufficient to pay the exercise price, (D) payment of such other lawful
consideration as the Compensation Committee may determine, or (E) any
combination of the foregoing.

         b. Valuation of Shares or Other Non-Cash Consideration Tendered in
            ---------------------------------------------------------------
Payment of Purchase Price.  For the purchase hereof, the fair market value of
-------------------------
any share of the Company's Common Stock or other non-cash consideration which
may be delivered to the Company in exercise of this option shall be determined
in good faith or in the manner determined by the Compensation Committee of the
Company from time to time.

         c. Delivery of Shares Tendered in Payment of Purchase Price.  If  the
            --------------------------------------------------------
Optionee exercises this option by delivery of shares of Common Stock of the
Company, the certificate or certificates representing the shares of Common Stock
of the Company to be delivered shall be duly executed in blank by the Optionee
or shall be accompanied by a stock power duly executed in blank suitable for
purposes of transferring such shares to the Company.  Fractional shares of
Common Stock of the Company will not be accepted in payment of the purchase
price of shares acquired upon exercise of this option.

         d. Restrictions on Use of Option Stock.  Notwithstanding the foregoing,
            -----------------------------------
no shares of Common Stock of the Company may be tendered in payment of the
purchase price of shares purchased upon exercise of this option if the shares to
be so tendered were acquired within six months before the date of such tender.
All shares tendered in payment of the purchase price must be fully vested.

     5.  DELIVERY OF SHARES; COMPLIANCE WITH SECURITIES LAWS, ETC.
         ---------------------------------------------------------

         a. General.  The Company will not be obligated to deliver any shares of
            -------
Stock pursuant to the Plan or to remove restriction from shares previously
delivered under the Plan (i) until all conditions of the option have been
satisfied or removed, (ii) until, in the opinion of the Company's counsel, all
applicable federal and state laws and regulations have been complied with, (iii)
if the outstanding Stock is at the time listed on any stock exchange, until the
shares to be delivered have been listed or authorized to be listed on such
exchange upon official notice of notice of issuance, and (iv) until all other
legal matters in connection with the issuance and delivery of such shares have
been approved by the Company's counsel.

         b. Listing, Qualification, etc.  This option shall be subject to the
            ---------------------------
requirements that if, at any time, counsel to the Company shall determine that
the listing, registration or qualification of the shares subject hereto upon any
securities exchange or under any state or federal law, or the consent or
approval of any governmental or regulatory body, or that the disclosure of non-
public information or the satisfaction of any other condition is necessary as a
condition of, or in connection with, the issuance or purchase of shares
hereunder, this option may not be exercised, in whole or in part, unless such
listing, registration, qualification, consent or approval, disclosure or
satisfaction of such other condition shall have been effected or obtained on
terms acceptable to the Compensation Committee.  Nothing herein shall be deemed
to require the Company to apply for, effect or obtain such listing,
registration, qualification or disclosure, or to satisfy such other condition.

                                     Page 3
<PAGE>

     6.  NON TRANSFERABILITY OF OPTION.  This option is personal and no rights
         -----------------------------
granted hereunder may be transferred, assigned, pledged or hypothecated in any
way (whether by operation of law or otherwise) nor shall any such rights be
subject to execution, attachment or similar process, except that this option may
be transferred (i) by will or the laws of descent and distribution or (ii)
pursuant to a qualified domestic relations order as defined in Section 414 (p)
of the Code.  Upon any attempt to transfer, assign, pledge, hypothecate or
otherwise dispose of this option or of such rights contrary to the provisions
hereof, or upon the levy of any attachment or similar process upon this option
or such rights, this option and such rights shall, at the election of the
Company, become null and void.

     7.  NO SPECIAL EMPLOYMENT OR SIMILAR RIGHTS.  Nothing contained in the Plan
         ---------------------------------------
or this Option shall be construed or deemed by any person under any
circumstances to bind the Company to continue the employment or other
relationship of the Optionee with the Company for the period within which this
option may be exercised.  The Company expressly reserves the right at any time
to dismiss the Optionee free from any liability or claim under the Plan, except
as otherwise expressly provided in this Agreement.

     8.  RIGHTS AS A SHAREHOLDER.  The Optionee shall have no rights as a
         -----------------------
shareholder with respect to any shares which may be purchased by exercise of
this option (including, without limitation, any rights to receive dividends or
non-cash distributions with respect to such shares) unless and until a
certificate representing such shares is duly issued and delivered to the
Optionee.  No adjustment shall be made for dividends or other rights for which
the record date is prior to the date such stock certificate is issued.

     9.  ADJUSTMENT PROVISIONS.  In the event that the Compensation
         ---------------------
Committee, in its sole discretion, determines that any stock dividend,
extraordinary cash dividend, recapitalization, reorganization, merger,
consolidation, split-up, spin-off, combination or other similar transaction
affects the Common Stock such that an adjustment is required in order to
preserve the benefits or potential benefits intended to be made available under
the Plan, then the Compensation Committee shall equitably adjust either or both
(i) the number and kind of shares subject to this option, and (ii) the award,
exercise or conversion price with respect to the foregoing, and if considered
appropriate, the Compensation Committee may make provision for a cash payment
with respect to this option, provided that the number of shares subject to this
option shall always be a whole number.

     10. MERGERS, CONSOLIDATION, DISTRIBUTIONS, LIQUIDATIONS, ETC.  In the event
         --------------------------------------------------------
of a consolidation, merger or other reorganization in which all of the
outstanding shares of Common Stock are exchanged for securities, cash or other
property of any other corporation or business entity (an "Acquisition") or in
the event of a liquidation of the Company, the Compensation Committee, or the
board of directors of any corporation assuming the obligations of the Company,
may, in its discretion, take any one or more of the following actions as to this
option:  (i)  provide that this option shall be assumed, or a substantially
equivalent option shall be substituted, by the acquiring or succeeding
corporation (or an affiliate thereof) on such terms as the Compensation
Committee determines to be appropriate, (ii) upon written notice to the
Optionee, provide that if unexercised, this option will terminate immediately
prior to the consummation of such transaction unless exercised by the Optionee
within a specified period following the date of such notice, (iii) in the event
of an Acquisition under the terms of which holders of the Common Stock of the
Company will receive upon consummation thereof a cash payment for each share
surrendered in the Acquisition (the "Acquisition Price"), make or provide for a
cash payment to the Optionee equal to the difference between (A) the Acquisition
Price

                                     Page 4
<PAGE>

times the number of shares of Common Stock subject to outstanding options
(to the extent then exercisable and to the extent the exercise price does not
exceed the Acquisition Price) and (B) the aggregate exercise price of all such
outstanding options in exchange for the termination of such options, and
(iv) provide that all or any outstanding options shall become exercisable or
realizable in full prior to the effective date of such Acquisition.

     11. WITHHOLDING TAXES.  The Company's obligation to deliver shares upon the
         -----------------
exercise of this option shall be subject to the Optionee's satisfaction of all
applicable federal, state and local income and employment tax withholding
requirements. The Optionee shall pay to the Company, or make provision
satisfactory to the Compensation Committee for payment of, any taxes required by
law to be withheld in respect of options under the Plan no later than the date
of the event creating the tax liability. In the Compensation Committee's
discretion, and subject to such conditions as the Compensation Committee may
establish, such tax obligations may be paid in whole or in part in shares of
Common Stock, including shares retained from the option creating the tax
obligation, valued at their fair market value. The Company may, to the extent
permitted by law, deduct any such tax obligations from any payment of any kind
otherwise due to the Optionee.

     12. MISCELLANEOUS.
         --------------

     (a) The Compensation Committee may amend, modify or terminate any
outstanding option, including substituting therefor another option of the same
or a different type, changing the date of exercise or realization, provided that
the Optionee's consent to such action shall be required unless the Compensation
Committee determines that the action, taking into account any related action,
would not materially and adversely affect the Optionee.  The Compensation
Committee may at any time accelerate the time at which all or any part of an
Option may be exercised.

     b)  All notices under this option shall be mailed or delivered by hand to
the parties at their respective addresses set forth beneath their names below or
at such other address as may be designated in writing by either of the parties
to one another.

    (c)  This option shall be governed by and construed in accordance with the
laws of the Commonwealth of Massachusetts without regard to its choice of law
provisions.

                         EPRESENCE, INC.

                         BY:
                                  ----------------------------------------------
                                  Richard M. Spaulding
                         Title:
                                  ----------------------------------------------
                                  Senior Vice President, Chief Financial Officer

                         Address: 120 Flanders Road
                                  Westboro, Massachusetts  01581

                                     Page 5
<PAGE>

                             OPTIONEE'S ACCEPTANCE

The undersigned hereby accepts the foregoing option and agrees to the terms and
conditions thereof.  The undersigned  hereby acknowledges receipt of a copy of
the Company's 2001 Stock Incentive Plan.

                                  OPTIONEE

                                  ----------------------------------------------

                                  Address:
                                           -------------------------------------

                                           -------------------------------------

                                     Page 6<PAGE>

                                                                   Exhibit 10.17

                                       *** Text Omitted and filed Separately
                                       Confidential Treatment Requested
                                       Under 17 C.F.R. (Sections) 200.80 (b)(4),
                                       200.83 and 240.24(b)-2.

               FIRST AMENDMENT AND FURTHER TERMS TO THE PRODUCT
                      DEVELOPMENT AND RESELLER AGREEMENT

     This FIRST AMENDMENT AND FURTHER TERMS TO THE PRODUCT DEVELOPMENT AND
RESELLER AGREEMENT ("Amendment"), dated this 30th day of March, 2001, amends the
Product Development and Reseller Agreement dated April 7, 2000 ("Reseller
Agreement") that was executed by and between Genomica Corporation ("Genomica")
and PE Corporation, by and through its PE Biosystems divisions, as follows:

     WHEREAS, the parties wish to amend certain terms of the Reseller Agreement;

     THEREFORE, the parties agree as follows:

     1.  Name Change Amendment.  All relevant Sections of the Reseller Agreement
shall be amended to incorporate the name change executed by PE Corporation,
changing PE Biosystems to "Applied Biosystems, Inc." (hereinafter "ABI").  In
the Reseller Agreement, all references to "PE Biosystems" are hereby amended to
"Applied Biosystems, Inc." and all references to "PEB" are hereby amended to
"ABI."

     2.  Consulting and Services Further Terms - ABI acknowledges that Genomica
has, since the execution of the Reseller Agreement until the date of this
Amendment, allocated substantial resources and incurred costs in support of ABI
achieving the Sales Milestones under the Agreement.  These resources and costs
include, but are not limited to, Genomica employees' ongoing time and effort
associated with developing marketing collateral, travel, training the ABI sales
force, participating in joint ABI/Genomica marketing meetings, and resolving
product integration issues, which are deemed by the parties to be over and above
that otherwise required of Genomica in the Reseller Agreement ("Extraordinary
Services").  ABI agrees to compensate Genomica for these Extraordinary Services
incurred in the first calendar quarter of 2001 by paying Genomica a one-time fee
of [***], payable within a reasonable time.

     3.  Sales Milestones Amendment.  Section 2.2 ("Conditional Exclusivity") is
hereby amended and replaced in its entirety by the following:

       2.2    Conditional Exclusivity

       ABI and Genomica acknowledge and agree that the grant of Exclusive
       distribution rights under Section 2.1 herein is in consideration of ABI's
       on-going achievement of the Sales Milestones, as defined in Exhibit D.
       In the event that ABI fails to either (i) achieve a Sales Milestone in
       two (2) consecutive quarters, or (ii) achieve 75% of the aggregate Sales
       Milestones for four (4) consecutive quarters, Genomica may, at its sole
       discretion, elect to cause this Agreement to change from conditionally
       Exclusive to a

* Confidential Treatment Requested
<PAGE>

       non-exclusive Agreement for the remainder of the term of the Agreement.
       For the period from the second quarter of 2001 through the first quarter
       of 2002, inclusive, ABI may choose to fulfill its Sales Milestone
       obligations by remitting quarterly payments to Genomica equal to the
       number of Genomica Product and Technical Support and Maintenance
       contracts that were to be sold by ABI for that quarter multiplied by the
       agreed upon fees for Genomica Product and Technical Support and
       Maintenance contracts to be paid to Genomica pursuant to Exhibit D.

     4.  Conditional Exclusivity Payment Further Terms.

       Genomica agrees to accept from ABI a one-time payment of [***], payable
       promptly following execution of this Amendment and in lieu of any other
       payment or consideration that may otherwise be called for under the
       Reseller Agreement or this Amendment, thereby allowing ABI to maintain
       its conditional exclusivity under the Reseller Agreement and nullifying
       any consequence under the Reseller Agreement for failing to meet any
       requirements for retention of exclusivity. Following this payment of
       [***], ABI's responsibility to meet its Sales Milestones pursuant to
       Exhibit D, or to fulfill its milestone obligations by making the
       quarterly payments specified in Section 2.2, shall commence on April 1,
       2001, as noted under Section 3 above of this Amendment.

[THE REST OF THIS PAGE INTENTIONALLY LEFT BLANK.]

* Confidential Treatment Requested
<PAGE>

     5.  Exhibit D.  Both tables in Exhibit D shall be amended as follows:

         Product Description                                Price
<TABLE>
<S>                                      <C>
-----------------------------------------------------------------------------------------
Genomica Product - List Price               [***] list price per unit

                                            Genomica to receive [***] of the [***] price.
-----------------------------------------------------------------------------------------
Genomica Product - Package Price            [***] package price per unit

[***] when [***] with AB hardware [***] to  Genomica to receive [***] of the [***] price.
GeneMapper (e.g. [***])
-----------------------------------------------------------------------------------------
Genomica Product - Multiple Units           [***] multiple units price per unit
Price

[***] for any [***] that [***] or more      Genomica to receive [***] of the [***] price.
LinkMapper [***] at [***]. This price
applies only to [***] purchased [***]
the [***]. The [***] is priced per
boxes one or two above.
-----------------------------------------------------------------------------------------
Technical Support and Maintenance           [***] per Genomica Product per year
Agreement

[***] Genomica Product units [***] be       Genomica to receive [***] of [***] price
sold with the Technical Support             North America and Europe for the first
and Maintenance fee.                        year, and 100% in subsequent years.

                                            Genomica will be responsible for customer
                                            invoicing and collections beginning on
                                            the anniversary date of year 1 and in all
                                            subsequent years in North America and
                                            Europe.

                                            Genomica to receive [***] of [***] price for
                                            outside of North America and Europe for
                                            the first and subsequent years.

                                            ABI will be responsible for customer
                                            invoicing and collections for all support
                                            contracts sold outside of North America
                                            and Europe.
-----------------------------------------------------------------------------------------
</TABLE>

*Confidential Treatment Requested

<PAGE>

Sales Milestones

<TABLE>
<CAPTION>
Sales Milestone
----------------------------------------------------------------------------
<S>                         <C>
Q2'01                       [***] product and maintenance agreements sold
----------------------------------------------------------------------------
Q3'01                       [***] product and maintenance agreements sold
----------------------------------------------------------------------------
Q4'01                       [***] product and maintenance agreements sold
----------------------------------------------------------------------------
Q1'02                       [***] product and maintenance agreements sold
----------------------------------------------------------------------------
Q2'02                       [***] product and maintenance agreements sold
----------------------------------------------------------------------------
Q3'02                       TBD 30 days prior to Q3'02
----------------------------------------------------------------------------
Q4'02                       TBD 30 days prior to Q3'02
----------------------------------------------------------------------------
Q1'03                       TBD 30 days prior to Q3'02
----------------------------------------------------------------------------
Q2'03                       TBD 30 days prior to Q3'02
----------------------------------------------------------------------------
</TABLE>

     6.  Entire Agreement.  This Amendment, together with the Reseller
Agreement, constitutes the final, complete and exclusive statement of the
agreement between the parties pertaining to their subject matter and supersedes
any and all prior and contemporaneous understandings or agreements of the
parties.

     7.  Modification.  This Amendment may be supplemented, amended or modified
only by the mutual agreement of the parties.  No supplement, modification or
amendment of this Amendment shall be binding unless it is in writing and signed
by both parties.

     8.  Inconsistency.  In the event of any conflict between this Amendment and
the Reseller Agreement, the terms of this Amendment shall govern.

     9.  Reseller Agreement Continuance.  Except with respect to the changes
effected by this Amendment, the Reseller Agreement continues to remain in full
force and effect.

IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be signed
by duly authorized officers or representatives on March 30, 2001.

[GENOMICA]                               [APPLIED BIOSYSTEMS, INC.]

    /s/   Kenneth S. Rubin                  /s/ Robert C. Jones
---------------------------------------  ---------------------------------------
Name:     Kenneth S. Rubin               Name:  Robert C. Jones
Title:    EVP of Commercial Development  Title: Vice President
Date:     March 30, 2001                 Date: March 30, 2001

*Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]